Pro Medicus (ASX:PME): Medical Imaging Software, US Contract Expansion and Growth Outlook

Sonal Goyal

09 September 2026 10:47 PM AEST

Pro Medicus (ASX:PME): Medical Imaging Software, US Contract Expansion and Growth Outlook

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Pro Medicus shares were priced at A$166.51 on 9 September 2026.
The company’s Investment story centres on cloud-based medical imaging software and transaction-linked Revenue from healthcare customers.
A seven-year, A$25 million Valley Health contract adds to the company’s North American customer footprint.
Execution, customer concentration, contract conversion and continued product relevance remain important factors for investors to monitor.

Pro Medicus Limited (ASX:PME) was priced at A$166.51 on 9 September 2026. With the share price remaining a key point of investor attention, the underlying debate around PME is increasingly tied to whether the company can continue converting its medical imaging technology into long-duration healthcare contracts and recurring transaction-based revenue. Pro Medicus provides healthcare informatics software to hospitals, imaging centres and health systems, with its Visage 7 platform spanning radiology workflow, image viewing, archive and related digital imaging functions.

Cloud Imaging Model

The company’s core appeal comes from a software model designed for large-scale healthcare imaging environments. Visage 7 can be deployed through cloud infrastructure and is built to handle high imaging volumes across complex hospital networks. This matters because radiology departments depend on speed, reliability, clinician access and interoperability. For Pro Medicus, expanding from a viewer or workflow deployment into a broader “full stack” implementation can deepen the commercial relationship and increase the range of services used by a customer.

US Contract Expansion

Separately, in August 2026 Pro Medicus announced a seven-year, A$25 million contract with Valley Health. The agreement extends the company’s presence in the US healthcare market and adds another multi-year deployment to its contract base. For investors, the significance lies less in any single contract and more in whether this pattern of large health-system wins can continue across new customers and existing accounts. The transaction-based licensing model also means usage growth can influence the Economics of individual contracts over time.

Why Scale Matters

Pro Medicus operates in a segment where enterprise healthcare customers tend to place a premium on system performance, data accessibility, security and workflow efficiency. Its commercial model benefits when customers standardise more of their imaging environment on the Visage platform. This can create a longer relationship than a single software installation and may support Recurring Revenue as imaging volumes grow. The company’s offices in Melbourne, Berlin and San Diego also reflect the international nature of its customer base and sales opportunity.

Investor Considerations

The company still faces execution risks that matter to the share story. Large healthcare contracts can involve lengthy implementation programs, integration with existing systems and demanding service expectations. Revenue concentration around major customers can increase the importance of contract retention and renewal. Competition in medical imaging software also remains relevant, particularly as hospital systems weigh cloud migration, interoperability, artificial intelligence integration and total cost of ownership when selecting technology partners.

What to Watch Next

Investors may monitor the pace of new contract wins, expansion within existing customer networks, progress on cloud-based deployments and the degree to which customers adopt more of the Visage platform. Further evidence of transaction-based revenue scaling, successful implementations and broader adoption across large health systems would help investors assess whether the company’s commercial model is continuing to deepen. Product development and integration of imaging workflows with emerging AI capabilities are also likely to remain relevant to the longer-term story.

Conclusion

Pro Medicus remains a healthcare technology company whose share performance is closely watched against the backdrop of a specialised medical imaging platform and a growing base of long-duration customer relationships. The A$166.51 share price on 9 September 2026 provides the market reference point, while the more durable questions concern contract conversion, customer expansion, cloud adoption and execution. The Valley Health agreement adds another data point to that broader commercial trajectory without defining the investment story on its own.

FAQs

Q: What does Pro Medicus do?

A: Pro Medicus provides medical imaging software and healthcare informatics solutions, principally through its Visage 7 platform.

Q: What is the Pro Medicus ASX ticker?

A: Pro Medicus trades on the Australian Securities Exchange under the ticker ASX:PME.

Q: What was the announced Valley Health contract?

A: Pro Medicus announced a seven-year, A$25 million contract with Valley Health in August 2026.

Q: What should investors monitor next?

A: Key areas include new contract wins, cloud implementations, customer expansion and wider adoption of the Visage platform.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.